[go: up one dir, main page]

PL2620153T3 - Zastrzyk 5alfa-androstano(alkilo)-3beta,5,6beta-triolu i sposób jego wytwarzania - Google Patents

Zastrzyk 5alfa-androstano(alkilo)-3beta,5,6beta-triolu i sposób jego wytwarzania

Info

Publication number
PL2620153T3
PL2620153T3 PL11826361T PL11826361T PL2620153T3 PL 2620153 T3 PL2620153 T3 PL 2620153T3 PL 11826361 T PL11826361 T PL 11826361T PL 11826361 T PL11826361 T PL 11826361T PL 2620153 T3 PL2620153 T3 PL 2620153T3
Authority
PL
Poland
Prior art keywords
beta
androstane
triol
alpha
alkyl
Prior art date
Application number
PL11826361T
Other languages
English (en)
Inventor
Guangmei Yan
Haiyan Hu
Jingxia Zhang
Pengxin Qiu
Ling Li
Ning TIAN
Original Assignee
Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Cellprotek Pharmaceutical Co., Ltd. filed Critical Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Publication of PL2620153T3 publication Critical patent/PL2620153T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PL11826361T 2010-09-21 2011-07-08 Zastrzyk 5alfa-androstano(alkilo)-3beta,5,6beta-triolu i sposób jego wytwarzania PL2620153T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010292234XA CN101961311B (zh) 2010-09-21 2010-09-21 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
EP11826361.5A EP2620153B1 (en) 2010-09-21 2011-07-08 5 alpha-androstane (alkyl)-3 beta,5,6 beta-triol injection and preparation method therefor
PCT/CN2011/076968 WO2012037834A1 (zh) 2010-09-21 2011-07-08 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法

Publications (1)

Publication Number Publication Date
PL2620153T3 true PL2620153T3 (pl) 2018-09-28

Family

ID=43514490

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11826361T PL2620153T3 (pl) 2010-09-21 2011-07-08 Zastrzyk 5alfa-androstano(alkilo)-3beta,5,6beta-triolu i sposób jego wytwarzania

Country Status (23)

Country Link
US (2) US9161985B2 (pl)
EP (1) EP2620153B1 (pl)
JP (1) JP5750680B2 (pl)
KR (1) KR101468153B1 (pl)
CN (1) CN101961311B (pl)
AU (1) AU2011304917B2 (pl)
BR (1) BR112013005763B1 (pl)
CA (1) CA2809646C (pl)
CY (1) CY1120724T1 (pl)
DK (1) DK2620153T3 (pl)
ES (1) ES2677069T3 (pl)
HR (1) HRP20181002T1 (pl)
HU (1) HUE038230T2 (pl)
LT (1) LT2620153T (pl)
PL (1) PL2620153T3 (pl)
PT (1) PT2620153T (pl)
RS (1) RS57409B1 (pl)
RU (1) RU2532354C1 (pl)
SG (2) SG188393A1 (pl)
SI (1) SI2620153T1 (pl)
SM (1) SMT201800426T1 (pl)
TR (1) TR201809354T4 (pl)
WO (1) WO2012037834A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN103626818B (zh) * 2012-03-08 2016-03-30 广州市赛普特医药科技有限公司 雄甾-3β,5α,6β-三醇的晶型化合物及其制备方法
CN103330946B (zh) * 2013-05-29 2015-03-25 广州市赛普特医药科技有限公司 5α-雄甾-3β,5,6β-三醇注射剂其制备方法
CN104288110B (zh) * 2013-06-26 2017-05-10 广州市赛普特医药科技股份有限公司 5α‑雄甾‑3β,5,6β‑三醇注射剂及其制备方法
US20160260519A1 (en) * 2013-09-26 2016-09-08 Polyone Corporation Sustainable poly(vinyl halide) mixtures for thin-film applications
CN109985047B (zh) * 2017-12-29 2021-07-27 广州市赛普特医药科技股份有限公司 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2191576A (en) * 1936-11-21 1940-02-27 Soc Of Chemical Ind 3,5,6-trihydroxy androstane and pregnane compounds
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
US5563131A (en) * 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
CA2237023C (en) * 1995-11-13 2008-02-19 Supergen, Inc. Improved formulation for administration of steroid compounds
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CN1232539C (zh) * 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
WO2004070048A1 (en) * 2003-02-07 2004-08-19 Pharmacia & Upjohn Company Llc A microbial process to prepare 5-androsten-3beta, 7alpha, 15alpha-triol-17-one and related analogues
CN1706501A (zh) 2005-05-27 2005-12-14 沈阳药科大学 亲脂性药物环糊精包合物的制备方法
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用

Also Published As

Publication number Publication date
EP2620153A4 (en) 2016-07-13
KR20130073945A (ko) 2013-07-03
CN101961311A (zh) 2011-02-02
CA2809646C (en) 2016-03-08
US9161985B2 (en) 2015-10-20
WO2012037834A1 (zh) 2012-03-29
HUE038230T2 (hu) 2018-10-29
EP2620153A1 (en) 2013-07-31
ES2677069T3 (es) 2018-07-27
AU2011304917B2 (en) 2014-10-23
SI2620153T1 (en) 2018-08-31
CY1120724T1 (el) 2019-12-11
TR201809354T4 (tr) 2018-07-23
HRP20181002T1 (hr) 2018-08-24
US20160051685A1 (en) 2016-02-25
CN101961311B (zh) 2012-11-21
SG188393A1 (en) 2013-04-30
JP5750680B2 (ja) 2015-07-22
RU2532354C1 (ru) 2014-11-10
SMT201800426T1 (it) 2018-09-13
BR112013005763B1 (pt) 2021-06-15
EP2620153B1 (en) 2018-04-18
LT2620153T (lt) 2018-10-10
CA2809646A1 (en) 2012-03-29
DK2620153T3 (en) 2018-07-23
US20130172307A1 (en) 2013-07-04
JP2013537170A (ja) 2013-09-30
RS57409B1 (sr) 2018-09-28
AU2011304917A1 (en) 2013-03-14
PT2620153T (pt) 2018-07-18
SG10201400723UA (en) 2014-10-30
KR101468153B1 (ko) 2014-12-01
US9265837B1 (en) 2016-02-23
BR112013005763A2 (pt) 2020-07-07
RU2013105216A (ru) 2014-10-27

Similar Documents

Publication Publication Date Title
ME03766B (me) Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe
DK3184136T3 (da) Injektor
PL3564361T3 (pl) Organoid wątroby, jego zastosowanie i sposoby hodowlane jego otrzymywania
BR112013033811A2 (pt) composição, método de preparação da composição, e, composto
EP2714970A4 (en) Enzyme QUANTIFICATION
EP2558999A4 (en) SOCIAL NETWORK HOMEPAGE
HUE037140T2 (hu) Humán GDF8-hoz kötõdõ ellenanyagok
HRP20170961T1 (hr) Postupak dobivanja karbamoilpiridonskih derivata i međuprodukata
EP2658805A4 (en) LIFT ASSEMBLY AND METHOD
PL2734049T3 (pl) Kompozycje probiotyczne i sposoby
BR112013010725A2 (pt) método, e, composição
EP2633007A4 (en) RENEWABLE BIO-ESSENCE PRODUCTION
EP2582664A4 (en) PHENYL THIOACETATE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
BR112014010450A2 (pt) composição e método
CO6781482A2 (es) Prevención de la agregación de biomasa en pozos de inyección
EP2740977A4 (en) Switching valve
EP2937687A4 (en) sample injector
PL2552484T3 (pl) Sposoby i preparaty służące do zmniejszenia poziomu hormonu przytarczyc
PL2688948T3 (pl) Sposób otrzymywania roztworu przyspieszacza
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
EP2620175A4 (en) INJEKTOR
BR112014009775A2 (pt) composição, método, semente e composto de fórmula 1
EP2712063A4 (en) PRESSURE FORMING STRUCTURE
PL2620153T3 (pl) Zastrzyk 5alfa-androstano(alkilo)-3beta,5,6beta-triolu i sposób jego wytwarzania
HRP20160918T1 (hr) Postupak pripreme 6-klor-2,3,4,9-tetrahidro-1h-karbazol-1-karboksamida i njegovih prekursora